Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation
10.19746/j.cnki.issn1009-2137.2024.01.053
- VernacularTitle:普乐沙福在自体移植外周血干细胞动员中应用策略的研究进展
- Author:
Ying FANG
1
;
Pei-Pei YE
Author Information
1. 宁波大学医学部
- Keywords:
plerixafor;
mobilization;
lymphoma;
multiple myeloma;
auto-HSCT
- From:
Journal of Experimental Hematology
2024;32(1):322-326
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Plerixafor,an analog of C-X-C motif chemokine receptor 4(CXCR4),which allows the release of stem cells from the bone marrow into peripheral blood(PB)by disrupting the interaction of CXCR4 with stromal cell-derived factor-1(SDF-1),is effective in mobilization for peripheral blood stem cells(PBSC).Due to its market approval has not been long and its high price in China,the clinical application of plerixafor is still very limited.The clinicians are actively seeking the optimal use of plerixafor to improve the success rate of PBSC collection and reduce the cost.This article reviews the latest research progress related to plerixafor application,in order to summarize the optimal use of plerixafor in autologous hematopoietic stem cell transplantation(auto-HSCT).
